Delving into the Latest Updates on KinoTeck Therapeutics Co., Ltd with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6

Top 5 Drug Type	Count

Small molecule drug	5
Chemical drugs	1

Top 5 Target	Count

FGFR2(Fibroblast growth factor receptor 2)	3
SOS1(Son of sevenless homolog 1)	1
p90 RSK(p90 RSK subfamily)	1
FGFR2 x FGFR3	1

This is a Phase1, open-label, dose escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of KNT-0916 in patients with unresectable or metastatic solid tumors harboring FGFR2 alterations who have failed prior systemic therapy. This study is divided into 2 parts, dose escalation part(part A), dose expansion part(partB).

Start Date10 Apr 2025

Sponsor / Collaborator

KinoTeck Therapeutics Co., Ltd

CTR20262718

/ Not yet recruitingPhase 1

评价KNT-0916片在中国健康参与者中的安全性和临床药理学特征的临床I期研究

[Translation] A Phase I clinical study evaluating the safety and clinical pharmacology of KNT-0916 tablets in healthy Chinese participants.

在中国健康参与者中评估不同类型饮食（低脂餐、高脂餐）对KNT-0916片的药代动力学（PK）特征的影响和KNT-0916片的安全性；

[Translation]

To evaluate the effects of different dietary types (low-fat meals and high-fat meals) on the pharmacokinetic (PK) characteristics and safety of KNT-0916 tablets in healthy Chinese participants;

Start Date-

Sponsor / Collaborator

KinoTeck Therapeutics Co., Ltd

100 Clinical Results associated with KinoTeck Therapeutics Co., Ltd

Login to view more data

0 Patents (Medical) associated with KinoTeck Therapeutics Co., Ltd

Login to view more data

100 Deals associated with KinoTeck Therapeutics Co., Ltd

Login to view more data

100 Translational Medicine associated with KinoTeck Therapeutics Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Sep 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

4

Preclinical

Phase 1

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

KNT-0916 ( FGFR2 )	Solid tumor More	Phase 1
BW-710 ( FGFR2 )	Neoplasms More	Preclinical
KNT-0919 ( FGFR2 x FGFR3 )	Stomach Cancer More	Preclinical
HW071021 ( SOS1 )	KRAS mutation-related tumors More	Preclinical
LHQ766 ( FGFR2 )	Neoplasms More	Preclinical